Kepler Capital Sticks to Its Buy Rating for Inditex (0QWI)
In a report released on June 11, Inigo Egusquiza from Kepler Capital maintained a Buy rating on Inditex (0QWI – Research Report), with a price target of €52.35. The company's shares closed last Wednesday at €47.06.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Egusquiza is a 5-star analyst with an average return of 11.1% and a 61.88% success rate.
In addition to Kepler Capital , Inditex also received a Buy from Jefferies's James Grzinic in a report issued on June 11. However, yesterday, Barclays reiterated a Hold rating on Inditex (LSE: 0QWI).
Based on Inditex's latest earnings release for the quarter ending July 31, the company reported a quarterly revenue of €9.92 billion and a net profit of €1.47 billion. In comparison, last year the company earned a revenue of €9.24 billion and had a net profit of €1.35 billion
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of 0QWI in relation to earlier this year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
5 top FTSE 100 stocks offering plenty of global growth for an ISA
The FTSE 100 is made up of the largest companies listed in London. But this doesn't mean that most stocks are UK-focused, far from it. In fact, it's quite straightforward to build a Stocks and Shares ISA portfolio of FTSE 100 shares that offer truly global exposure. Here are five that would certainly do the job. Let's start with the largest stock by market cap in the Footsie today: AstraZeneca (LSE: AZN). This healthcare giant has truly global operations, spanning the areas of oncology, respiratory and immunology, rare diseases, and more. This year, the firm is expected to rake in $57.5bn in revenue, with a net profit of about $14bn. And it generates this from nearly everywhere, including China and Japan. Region % of total revenue (2024) US 40% Europe 16% China 12% UK 9% Japan 6% Rest of world 17% As we can see, investors in AstraZeneca are getting diversified exposure to the whole of the developed world. The reason the US is such a sizeable part is because it has the largest healthcare system of them all. The stock has fallen 17.5% since the end of August, putting it on a forward price-to-earnings (P/E) ratio of 15.5. For a profitable firm of this calibre, which also offers a 2.3% dividend yield, I think that's very attractive. Turning to another FTSE 100 giant now, we have HSBC (LSE: HSBA). The bank is increasingly focused on Asia these days, as that's where most of the world's growth is expected to come from in future. Indeed, according to the Asian Development Bank, Asia's middle class is set to swell to roughly 3bn people by 2050. With HSBC increasingly focused on wealth management in the region, the long-term growth story looks very promising. This year, the bank is expected to earn around $23bn on revenue of almost $67bn. The stock is offering an attractive 5.8% dividend yield. The third stock is Airtel Africa. As the name implies, the firm's operations extend across Africa. Specifically, Airtel is a provider of telecommunications and mobile money services to 166m people in 14 countries in sub-Saharan Africa. The share price has been on a tear, surging 55% this year alone. However, it still looks decent value to me, trading at 12.5 times next year's forecast earnings. There's also a well-supported 2.8% dividend yield. Finally, for even more global portfolio exposure, investors could consider Coca Cola HBC and Coca-Cola Europacific Partners. These are both bottling partners for the US beverage giant, selling brands like Coca-Cola, Fanta, Sprite, and Monster. The former's markets include Western Europe and the Asia-Pacific region, including Australia, New Zealand, and the Philippines. The other's portfolio is more weighted toward emerging and developing markets, including Poland, Romania, Nigeria, and Egypt. Naturally, none of these five stocks are totally risk-free. The Coca-Cola bottlers could suffer during a severe global economic downturn, as this would put pressure on consumer spending. Meanwhile, HSBC and AstraZeneca may fall foul of regulatory changes in China, especially if trade tensions with the US worsen at some point. Finally, most of Airtel Africa's revenue is collected in local African currencies, but it's reported in US dollars, exposing the company to currency risk. Nevertheless, adding these stocks to an ISA would make it truly global, with vast exposure to Europe, America, Africa, and Asia. The post 5 top FTSE 100 stocks offering plenty of global growth for an ISA appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool HSBC Holdings is an advertising partner of Motley Fool Money. Ben McPoland has positions in AstraZeneca Plc, Coca-Cola Hbc Ag, and HSBC Holdings. The Motley Fool UK has recommended Airtel Africa Plc, AstraZeneca Plc, and HSBC Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
Capricor treatment of Becker muscular dystrophy granted orphan designation
The FDA granted orphan designation to a treatment of Becker muscular dystrophy being developed by Capricor, according to a post to the agency's website. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
2 hours ago
- Business Insider
Stifel Nicolaus Remains a Buy on RegenXBio (RGNX)
In a report released today, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on RegenXBio (RGNX – Research Report), with a price target of $40.00. The company's shares opened today at $9.72. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Samimy is a 4-star analyst with an average return of 4.0% and a 42.89% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, RegenXBio, and Altimmune. Currently, the analyst consensus on RegenXBio is a Strong Buy with an average price target of $31.27, representing a 221.71% upside. In a report released on May 28, Leerink Partners also maintained a Buy rating on the stock with a $19.00 price target.
